$ONC

BeOne Medicines (ONC) announced FDA approval for TEVIMBRA in combination with ZIIHERA and chemotherapy for HER2-positive gastroesophageal adenocarcinoma. The approval is based on Phase 3 trial data showing a median survival of 26.4 months. The company reported Q2 2026 revenue of $1.7 billion, up 30% YoY, and raised full-year revenue guidance to $6.6B-$6.8B. However, a Phase 3 study for zanubrutinib-sonrotoclax combination did not meet its primary endpoint.

President Trump's administration signed drug-pricing agreements with nine mid-sized pharmaceutical companies, including Astellas Pharma, Teva, and UCB, to lower U.S. drug prices under the MFN proposal. Companies agreed to reduce prices and invest $19.6B in U.S. manufacturing, with some contributing APIs to a government reserve. The deals cover 89% of the branded drug market, expanding beyond initial Big Pharma focus.

President Trump announced drug pricing agreements with nine pharmaceutical companies, including Alcon (ALC), BeOne (ONC), BridgeBio (BBIO), and Teva (TEVA). The deals require discounts on outpatient drugs for Medicaid and $19.6B in U.S. manufacturing investments. This expands the total to 26 companies, covering 90% of the U.S. market. The White House estimates $529B in savings over a decade.

BeOne Medicines agreed to reduce the price of its esophageal cancer drug, Tevimbra, under the US Medicaid program. The company is one of nine to comply with the US government's Most Favored Nation drug pricing policy. Tevimbra accounts for 13% of BeOne's total revenue, with global sales reaching nearly CNY3 billion in H1 2024. The company's shares fell in Shanghai, Hong Kong, and New York.

Nine drugmakers, including Alcon (ALC), Astellas, BeOne Medicines (ONC), BridgeBio (BBIO), and Teva (TEVA), agreed to lower U.S. drug prices and invest $19.6B in U.S. factories. Shares showed mixed after-hours reactions. The deals follow earlier agreements with larger pharma companies, covering 89% of the branded drug market.

BeOne Medicines (Nasdaq: ONC) agreed with the U.S. Government to expand cancer medicine access and boost U.S. manufacturing. The company committed to pricing future FDA-approved products competitively and invested $300M in its NJ facility, adding 120 jobs. BeOne aims to enhance supply continuity and support its oncology pipeline.

BeOne Medicines reported positive Phase 3 trial results for ZIIHERA (zanidatamab) plus chemotherapy, with and without TEVIMBRA (tislelizumab), in HER2+ gastroesophageal cancer. The study met its primary endpoint, showing statistically significant overall survival benefits. The FDA recently approved these regimens for first-line treatment. BeOne has rights to ZIIHERA in Asia, Australia, and New Zealand.

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Financial Information On August 26, 2026, BeOne Medicines Ltd. (the “Company”) filed its 2026 Interim Report for the six months ended June 30, 2026 (the “STAR Interim Report”) with the Science and Technology Innovation Board (the “STAR Market”) of the Shanghai Stock

BeOne Medicines (ONC) officer Xiaobin Wu plans to sell 15,000 ADS, acquired from RSU vesting between 2022 and 2023, according to a Form 144 filing. Wu sold 3,275 shares in June 2026, totaling $882,436.10. The sale is set for 2026 via Morgan Stanley.

BeOne Medicines (ONC) former director Corazon D. Sanders plans to sell 2,075 ADS worth $788,500 under Rule 144, via Morgan Stanley, on or after 08/25/2026. Sanders previously sold 945 shares for $250,893.81 in June 2026.